AbbVie and Galapagos Sign $405 Million Agreement
After recently signing an anti-inflammatory deal with Ablynx, AbbVie has now announced a new agreement with Galapagos in cystic fibrosis. Specifically, the organisations have confirmed that they will contribute technologies and resources to develop oral drugs that address the main mutations in cystic fibrosis patients, including F508del and G551D, with the intention of starting Phase